Possibilities of Autologous Fecal Microbiota Transplantation in patients with obesity and diabetes mellitus
https://doi.org/10.14341/omet12901
Abstract
Obesity and type 2 diabetes mellitus (T2DM) are major problems for public health all over the world. According to retrospective research, the prevalence of obesity has doubled in more than 70 countries since 1980, as well as the prevalence of obesity complications (atherosclerotic cardiovascular diseases, nonalcoholic fatty liver disease and their complications. There are many drug therapies for T2DM, but it is difficult to achieve a stable, clinically relevant effect on a long-term basis. The fact that a patient has both conditions makes it difficult to optimize carbohydrate metabolism and to achieve normal body weight. Many antidiabetic drugs cause weight again, which, in turn, contributes to the growth of insulin resistance (IR) and requires further intensification of therapy.
In the last few years, there is a growing evidence of the relationship between the gut microbiota (GM), obesity and T2DM. There has been a steady growth of interest in such medical technology as fecal microbiota transplantation (FMT) in the world. Since there is data on the association of the gut microbiota (GM) with the development of IR and T2DM, the possibility of FMT can potentially be one of the new methods of treatment. This review presents the current state of the problem and discusses the possibility of modifying GM as a therapeutic strategy in obesity and T2DM with an accent on autologous fecal microbiota transplantation.
About the Authors
R. M. Guseinova
Endocrinology Research Centre
Russian Federation
Russian Federation
Raisat M. Guseinova, MD
11, Dm. Ulyanova street, 117036 Moscow
eLibrary SPIN: 9719-3850
E. A. Shestakova
Endocrinology Research Centre
Ekaterina A. Shestakova, MD, PhD
Moscow
eLibrary SPIN: 1124-7600
References
1. NIH HMP Working Group, Peterson J, Garges S, et al. The NIH Human Microbiome Project. Genome Res. 2009; 19(12):2317-2323. doi:10.1101/gr.096651.109
2. Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56-64. doi:10.1038/nature18846
3. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718-15723. doi:10.1073/pnas.0407076101
4. Schroeder BO, Bäckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22(10):1079-1089. doi:10.1038/nm.4185
5. Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23(7):859-868. doi:10.1038/nm.4358
6. Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. 2019;63(2):101-108. doi: https://doi.org/10.1016/j.jnutbio.2018.10.003
7. Kang D-W, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep. 2019;9(1):5821. doi: https://doi.org/10.1038/s41598-019-42183-0
8. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. 2017;20(2):145-155. doi: https://doi.org/10.1038/nn.4476
9. Yu F, Han W, Zhan G, et al. Abnormal gut microbiota composition contributes to the development of type 2 diabetes mellitus in db/db mice. Aging (Albany NY). 2019;11(22):10454-10467. doi: https://doi.org/10.18632/aging.102469
10. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222-227. Published 2012 May 9. doi:10.1038/nature11053
11. Ussar S, Griffin NW, Bezy O, et al. Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome [published correction appears in Cell Metab. 2016 Mar 8;23(3):564-6]. Cell Metab. 2015;22(3):516-530. doi:10.1016/j.cmet.2015.07.007
12. Goodrich JK, Waters JL, Poole AC, et al. Human genetics shape the gut microbiome. Cell. 2014;159(4):789-799. doi:10.1016/j.cell.2014.09.053
13. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105-108. doi:10.1126/science.1208344
14. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota [published correction appears in Nature. 2017 May 3;545(7652):116]. Nature. 2015;528(7581):262-266. doi:10.1038/nature15766
15. Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560-564. doi:10.1126/science.aad3503
16. Charbonneau MR, Blanton LV, DiGiulio DB, et al. A microbial perspective of human developmental biology. Nature. 2016;535(7610):48-55. doi:10.1038/nature18845
17. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031. doi:10.1038/nature05414
18. Mackowiak PA. Recycling metchnikoff: probiotics, the intestinal microbiome and the quest for long life. Front Public Health. 2013;1:52. Published 2013 Nov 13. doi:10.3389/fpubh.2013.00052
19. Grigoroff S. Revue Medicale de la Suisse Romande. Geneve: Georg&G; 1905
20. Scott KP, Antoine J-M, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Heal Dis. 2015;26(2):145-155. doi: https://doi.org/10.3402/mehd.v26.25877
21. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection [published correction appears in JAMA. 2015 Feb 17;313(7):729]. JAMA. 2014;312(17):1772-1778. doi:10.1001/jama.2014.13875
22. McCune VL, Struthers JK, Hawkey PM. Faecal transplantation for the treatment of Clostridium difficile infection: a review. Int J Antimicrob Agents. 2014;43(3):201-206. doi:10.1016/j.ijantimicag.2013.10.009
23. Austin M., Mellow M., Tierney W. M. Fecal microbiota transplantation in the treatment of Clostridium difficile infections //The American journal of medicine. – 2014. – Т. 127. – №. 6. – С. 479-483.
24. Aron-Wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Curr Diab Rep. 2019;19(8):51. doi: https://doi.org/10.1007/s11892-019-1180-z
25. Kootte RS, Levin E, Salojärvi J, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017;26(4):611-619.e6. doi:10.1016/j.cmet.2017.09.008
26. Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-2115. doi:10.1136/gutjnl-2018-316434
27. Ng SC, Xu Z, Mak JWY, et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut. 2022;71(4):716-723. doi:10.1136/gutjnl-2020-323617
28. Wang H, Lu Y, Yan Y, et al. Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets. Front Cell Infect Microbiol. 2020;9:455. Published 2020 Jan 17. doi:10.3389/fcimb.2019.00455
29. F. Backhed, H. Ding, T. Wang, L.V. Hooper, G.Y. Koh, A. Nagy, et al. The gut microbiota as an environmental factor that regulates fat storage Proc Natl Acad Sci U S A, 101 (2004), pp. 15718-15723 https://doi.org/10.1073/pnas.0407076101
30. M.T. Khan, M. Nieuwdorp, F. Backhed Microbial modulation of insulin sensitivity Cell Metab, 20 (2014), pp. 753-760 https://doi.org/10.1016/j.cmet.2014.07.006
31. S. Rabot, M. Membrez, A. Bruneau, P. Gerard, T.Harach, M. Moser, et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism FASEB J Off Publ Fed Am Soc Exp Biol, 24 (2010), pp. 4948-4959 https://doi.org/10.1096/fj.10-164921
32. P.J. Turnbaugh, R.E. Ley, M.A. Mahowald, V. Magrini, E.R. Mardis, J.I. Gordon An obesity-associated gut microbiome with increased capacity for energy harvest Nature, 444 (2006), pp. 1027-1031 https://doi.org/10.1038/nature05414
33. Yu EW, Gao L, Stastka P, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebocontrolled pilot trial. PLOS Med. 2020;17(3):e1003051. doi: https://doi.org/10.1371/journal.pmed.1003051
34. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome [published correction appears in Gastroenterology. 2013 Jan;144(1):250]. Gastroenterology. 2012;143(4):913-6.e7. doi:10.1053/j.gastro.2012.06.031
35. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500-508. doi:10.1038/ajg.2013.59
36. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049. doi:10.1016/j.cgh.2011.08.014
37. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415. doi:10.1056/NEJMoa1205037
38. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515-1522. doi:10.1093/cid/ciu135
39. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994-1002. doi:10.1093/cid/cir632
40. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, et al.. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol [Internet] 2011; 9:1044-9. Available from: http://dx.doi.org/ 10.1016/j.cgh.2011.08.014; PMID:21871249; http://dx.doi.org/ 10.1016/j.cgh.2011.08.014 [PMC free article] [PubMed] [CrossRef] [CrossRef] [Google Scholar]
41. Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019;68(12):2111-2121. doi:10.1136/gutjnl-2019-319548
42. Terveer EM, van Beurden YH, Goorhuis A, et al. How to: Establish and run a stool bank. Clin Microbiol Inf. 2017;23(12):924-30. doi: 10.1016/j.cmi.2017.05.015
43. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-80. doi: 10.1136/gutjnl-2016-313017
44. Mullish BH, Quraishi M, Segal J, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;0:1-22. doi: 10.1136/gutjnl-2018-316818
45. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979-984. doi:10.1073/pnas.0605374104
46. Xiao L, Yan J, Yang T, et al. Fecal Microbiome Transplantation from Children with Autism Spectrum Disorder Modulates Tryptophan and Serotonergic Synapse Metabolism and Induces Altered Behaviors in Germ-Free Mice. mSystems. 2021;6(2):e01343-20. Published 2021 Apr 6. doi:10.1128/mSystems.01343-20
47. Pu Y, Tan Y, Qu Y, et al. A role of the subdiaphragmatic vagus nerve in depression-like phenotypes in mice after fecal microbiota transplantation from Chrna7 knock-out mice with depression-like phenotypes. Brain Behav Immun. 2021;94:318-326. doi:10.1016/j.bbi.2020.12.032
48. https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission
49. Janket SJ, Ackerson LK, Diamandis EP. Drug-Resistant Bacteremia after Fecal Microbiota Transplant. N Engl J Med. 2020;382(20):1960. doi:10.1056/NEJMc2002496
50. Kassam Z, Dubois NE, Ling K. 512 – donor health screening for fecal microbiota transplantation: prospective evaluation of 15,317 candidate donors. Gastroenterology. 2019;156:100-1. doi: 10.1016/S0016- 5085(19)37042-8 45.
51. Paramsothy S, Borody TJ, Lin E, et al. Donor Recruitment for Fecal Microbiota Transplantation. Inflamm Bowel Dis. 2015;21(7):1600-1606. doi:10.1097/MIB.0000000000000405
52. Pérez-Matute P, Íñiguez M, de Toro M, Recio-Fernández E, Oteo JA. Autologous fecal transplantation from a lean state potentiates caloric restriction effects on body weight and adiposity in obese mice. Sci Rep. 2020;10(1):9388. Published 2020 Jun 10. doi:10.1038/s41598-020-64961-x
53. Lundberg R, Toft MF, August B, Hansen AK, Hansen CH. Antibiotic-treated versus germ-free rodents for microbiota transplantation studies [published correction appears in doi: 10.1038/srep05922]. Gut Microbes. 2016;7(1):68-74. doi:10.1080/19490976.2015.1127463
54. Li SS, Zhu A, Benes V, et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science. 2016;352(6285):586-589. doi:10.1126/science.aad8852
55. Smillie CS, Sauk J, Gevers D, et al. Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. Cell Host Microbe. 2018;23(2):229-240.e5. doi:10.1016/j.chom.2018.01.003
56. de Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut 2020:gutjnl-2020-322630
57. Rinott E, Youngster I, Yaskolka Meir A, et al. Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain. Gastroenterology. 2021;160(1):158-173.e10. doi:10.1053/j.gastro.2020.08.041
58. Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nature Medicine. 2021 Jul;27(7):1272-1279. DOI: 10.1038/s41591-021-01399-2. PMID: 34226737.
59. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; (44): 854–9.
60. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334-339. doi:10.1056/NEJMcp011603
61. Suvorov A, Karaseva A, Kotyleva M, et al. Autoprobiotics as an Approach for Restoration of Personalised Microbiota. Front Microbiol. 2018;9:1869. Published 2018 Sep 12. doi:10.3389/fmicb.2018.01869
62. Azad MAK, Sarker M, Li T, Yin J. Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed Res Int. 2018;2018(3):1-8. doi:https://doi.org/10.1155/2018/9478630
63. Suez J, Zmora N, Zilberman-Schapira G, et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell. 2018;174(6):1406-1423.e16. doi:10.1016/j.cell.2018.08.047
Review
For citations:
Guseinova R.M., Shestakova E.A. Possibilities of Autologous Fecal Microbiota Transplantation in patients with obesity and diabetes mellitus. Obesity and metabolism. 2022;19(3):300-305. (In Russ.) https://doi.org/10.14341/omet12901
Views:
868
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
